Finished product reference
Cinnarizine
Tablet · Oral · 75 mg
- List code
- 293
- Pharmacologic class
- Antihistamine (piperazine derivative) with calcium-channel blocking activity; antiemetic / antivertigo agent
What it is and how it works
Cinnarizine blocks H1 receptors and inhibits calcium influx into vascular smooth muscle and vestibular sensory cells, reducing vestibular stimulation and labyrinthine excitability. It also has mild antimuscarinic and antidopaminergic activity.
Indications
Vestibular disorders such as vertigo, tinnitus, nausea and vomiting in Ménière’s disease; prevention of motion sickness.
Dosage and administration (summary)
Oral (adults): vestibular disorders, 30 mg three times daily; motion sickness, 30 mg 2 hours before travel, then 15 mg every 8 hours during the journey if required.
Contraindications
Hypersensitivity to cinnarizine; acute porphyria.
Warnings and precautions
Drowsiness is common and is increased by alcohol and CNS depressants; patients should not drive if affected. Extrapyramidal symptoms, sometimes with depression, may occur, particularly with prolonged use in the elderly; avoid in Parkinson’s disease. Use with caution in hypotension, hepatic or renal impairment.
Pregnancy
Avoid in pregnancy unless the benefit outweighs the risk.
Storage and supply
Store below 25 °C, protected from light and moisture.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.